Four Type 2 diabetes drugs are in CMS' lineup of the 10 drugs that face price negotiations between the agency and their makers. 

Some payers aren't covering the recently approved vaccines for respiratory syncytial virus, leaving older adults to cough up $330 out of pocket, The New York Times reported Aug. 25. 

While some hospitals are paying five to 10 times more for cancer drugs during a monthslong shortage, the U.S. saw 14 new drug supply issues since early August. 

Philadelphia-based Fox Chase Cancer Center named Dapo Amosu, PharmD, as its senior pharmacy director. 

Rite Aid is preparing to file for Chapter 11 bankruptcy this fall as it faces numerous lawsuits over its alleged role in the opioid epidemic, people familiar with the matter told The Wall Street Journal. 

The Hawaii Department of Health and Honolulu-based Kapiolani Medical Center for Women and Children have agreed to partner in purchasing a year's supply of mifepristone — equivalent to 1,000 doses, according to an Aug. 24 news release. 

Matthew Jenkins, PharmD, will become Richmond, Va.-based VCU Health's first chief pharmacy officer on Sept. 17. 

CVS unveiled Cordavis, a new subsidiary focused on biosimilars in the U.S., on Aug. 23.

Two medications, ephedrine sulfate and hydroxychloroquine sulfate, were denied inclusion on the FDA's 503B bulks list, the agency said Aug. 21. 

The FDA warned Amazon, Walmart and two other companies for selling products for molluscum contagiosum — a viral skin infection that does not have any approved over-the-counter treatments.